17-Hydroxyprogesterone caproate in triplet pregnancy: an individual patient data meta-analysis

C. A. Combs*, E. Schuit, S. N. Caritis, A. C. Lim, T. J. Garite, K. Maurel, D. Rouse, E. Thom, A. T. Tita, B. W. J. Mol

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

11 Citations (Web of Science)


Preterm birth complicates almost all triplet pregnancies and no preventive strategy has proven effective.To determine, using individual patient data (IPD) meta-analysis, whether the outcome of triplet pregnancy is affected by prophylactic administration of 17-hydroxyprogesterone caproate (17OHPc).We searched literature databases, trial registries and references in published articles.Randomised controlled trials (RCTs) of progestogens versus control that included women with triplet pregnancies.Investigators from identified RCTs collaborated on the protocol and contributed their IPD. The primary outcome was a composite measure of adverse perinatal outcome. The secondary outcome was the rate of birth before 32?weeks of gestation. Other pre-specified outcomes included randomisation-to-delivery interval and rates of birth at
Original languageEnglish
Pages (from-to)682-690
JournalBjog-an International Journal of Obstetrics and Gynaecology
Issue number5
Publication statusPublished - Apr 2016


  • 17-Hydroxyprogesterone caproate
  • multiple gestation
  • preterm birth prevention
  • progestogens
  • triplet pregnancy

Cite this